Alexander Bystritsky
Psychiatry · Los Angeles, CANPI 1053428011
Payments from drug & device makers
Across 99 payments — averaging $8044.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$303K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$162K
- Boehringer Ingelheim$131K
- Biohaven Pharmaceuticals, Inc.$73K
- Takeda Pharmaceuticals U.S.A., Inc.$31K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$30K
- plus $65K from 12 others
Across 8 payments — averaging $5163.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Brainsway USA Inc$40K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$1K
What the payments were for
- Consulting fees$7,64383%
- Travel & lodging$7168%
- Food & beverage$88610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 27 | $303,370 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 13 | $162,453 |
| Boehringer Ingelheim | 11 | $130,956 |
| Biohaven Pharmaceuticals, Inc. | 7 | $73,208 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $30,664 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $30,273 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $30,175 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 3 | $17,175 |
| Avanir Pharmaceuticals, Inc. | 3 | $6,557 |
| AMAG Pharmaceuticals, Inc. | 3 | $6,203 |
| AbbVie | 2 | $4,990 |
| Sunovion Pharmaceuticals Inc. | 5 | $139 |
| Vanda Pharmaceuticals Inc. | 3 | $71 |
| Novo Nordisk | 4 | $63 |
| Adlon Therapeutics L.p. | 2 | $40 |
| Merz North America, Inc. | 1 | $25 |
| Johnson & Johnson | 1 | $23 |
| Lundbeck LLC | 1 | $20 |
How this compares
$796,407 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trazodone Hcl | 25 | $237 |
| Gabapentin | 19 | $167 |
| Eszopiclone | 11 | $156 |
| Zolpidem Tartrate | 12 | $130 |
| Sertraline Hcl | 22 | $30 |
| Diazepam | 13 | $8 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Los Angeles
- Lon SchneiderLos Angeles$1.8M
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.